N
|
384
|
248
|
248
|
399
|
249
|
250
|
250
|
246
|
367
|
398
|
400
|
3439
|
HIV + ve
|
69 (18%)
|
90 (38%)
|
133 (56%)
|
220 (55%)
|
199 (80%)
|
101 (40%)
|
122 (49%)
|
97 (41%)
|
22 (6%)
|
65 (16%)
|
140 (35%)
|
1258 (37%)
|
HBsAg + ve
|
13 (3%)
|
8 (3%)
|
10 (4%)
|
17 (4%)
|
13 (5%)
|
9 (4%)
|
10 (4%)
|
6 (2%)
|
20 (5%)
|
15 (4%)
|
20 (5%)
|
141 (4%)
|
Anti-HCV + ve ELISA
|
1 (< 1%)
|
0
|
0
|
0
|
0
|
16 (6%)
|
3 (1%)
|
1 (< 1%)
|
136 (37%)
|
113 (28%)
|
288 (72%)
|
558 (16%)
|
HCV viral load detectable
|
0
|
0
|
0
|
0
|
0
|
15 (6%)
|
2 (1%)
|
0
|
102 (28%)
|
90 (23%)
|
227 (57%)
|
436 (13%)
|
HCV viraemic rate (among anti_HCV + ve)
|
0
|
0
|
0
|
0
|
0
|
94%
|
67%
|
0
|
75%
|
80%
|
79%
|
78%
|
Anti-HCV-HIV co-infection
|
0
|
0
|
0
|
0
|
0
|
6 (2%)
|
3 (1%)
|
1 (< 1%)
|
10 (3%)
|
25 (6%)
|
113 (28%)
|
158 (5%)
|
Anti-HCV prevalence among HIV + ve participants
|
0
|
0
|
0
|
0
|
0
|
6 (6%)
|
3 (2%)
|
1 (1%)
|
10 (45%)
|
25 (38%)
|
113 (81%)
|
158 (13%)
|
Anti-HCV-HBV co-infection
|
0
|
0
|
0
|
0
|
0
|
1 (< 1%)
|
0
|
0
|
5 (1%)
|
5 (1%)
|
17 (4%)
|
28 (< 1%)
|
HIV-HBsAg co-infection
|
5 (1%)
|
3 (1%)
|
9 (4%)
|
13 (3%)
|
12 (5%)
|
5 (2%)
|
7 (3%)
|
3 (1%)
|
3 (1%)
|
6 (2%)
|
9 (2%)
|
75 (2%)
|
HIV-anti-HCV-HBV co-infection
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2 (1%)
|
8 (2%)
|
10 (< 1%)
|